Rosa M. Nadal Rios, MD, PhD

Dr. Nadal serves as an Associate Research Physician in the Cellular and Molecular Therapeutics Branch. She specializes in the treatment of patients with genitourinary cancers, including kidney and bladder cancer. Her primary objective as an investigator is to advance innovative therapies, particularly immunotherapy and cellular therapy, while delivering personalized care to patients with urologic cancers.

Dr. Nadal obtained her medical and PhD degrees from Universitat Autònoma de Barcelona and completed her residency at The Hospital de la Santa Creu i San Pau in Barcelona. She furthered her training with a hematology/oncology fellowship at the National Institutes of Health in Bethesda, Maryland. Her clinical research has shed light on the limited efficacy of sequential androgen receptor signaling inhibitor use in most patients with advanced metastatic castration-resistant prostate cancer. She has also made significant contributions to the clinical development of targeted therapies, either alone or in combination with immunotherapy and cellular therapy, for the treatment of kidney and bladder cancer.

Publications:

Progress in systemic therapy for advanced-stage urothelial carcinoma

Systemic therapy issues: Immunotherapy in nonmetastatic urothelial cancer

Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial

Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors

AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer